Views: Visits 17
(FILES) In this file photo taken on December 9, 2020, a health worker prepares a syringe to inoculate a volunteer with a COVID-19 vaccine produced by China’s Sinopharm during its trial at the Clinical Studies Center of the Cayetano Heredia University in Lima. – Phase 3 trials of a Sinopharm coronavirus vaccine found it was 79 percent effective, the Chinese pharma giant said on December 30, 2020, lower than rival jabs developed by Pfizer-BioNTech and Moderna but a potential breakthrough in the battle to stem the pandemic in Asia. (Photo by ERNESTO BENAVIDES / AFP)
Phase 3 trials of a Sinopharm coronavirus vaccine found it was 79 percent effective, the Chinese pharma giant said Wednesday, lower than rival jabs developed by Pfizer-BioNTech and Moderna but a potential breakthrough in the battle to stem the pandemic in Asia.
(FILES) In this file photo taken on December 9, 2020, a health worker prepares a syringe to inoculate a volunteer with a COVID-19 vaccine produced by China’s Sinopharm during its trial at the Clinical Studies Center of the Cayetano Heredia University in Lima. – Phase 3 trials of a Sinopharm coronavirus vaccine found it was 79 percent effective, the Chinese pharma giant said on December 30, 2020, lower than rival jabs developed by Pfizer-BioNTech and Moderna but a potential breakthrough in the battle to stem the pandemic in Asia. (Photo by ERNESTO BENAVIDES / AFP)
Phase 3 trials of a Sinopharm coronavirus vaccine found it was 79 percent effective, the Chinese pharma giant said Wednesday, lower than rival jabs developed by Pfizer-BioNTech and Moderna but a potential breakthrough in the battle to stem the pandemic in Asia.
Posted : 2020-12-13 09:18
Updated : 2020-12-13 11:08
A health worker prepares a syringe to inoculate a volunteer with a COVID-19 vaccine produced by the Chinese Sinopharm during its trial at the Clinical Studies Center of the Cayetano Heredia University in Lima on Dec. 9, 2020. AFP
Peru suspended trials for China s Sinopharm COVID-19 vaccine due to a serious adverse event that occurred with one of the volunteers for the study, the Peruvian government said in a statement on Saturday.
The health ministry said the event is under investigation to determine if it is related to the vaccine or if there is another explanation.
Peru announces Sinopharm vaccine trial suspension following adverse event
The Peruvian government Saturday announced the suspension of trials for the Chinese Sinopharm vaccine against COVID-19 after a serious adverse event was recorded in one of the trial participants, according to Reuters.
In statements, the ministry of health said that the occurence is currently under investigation to detemine whether the serious reaction was related to the vaccine or otherwise, adding that the temporary suspension is merely a safety measure to ensure the health of the participants.
According to Reuters, the Chief Researcher at Cayetano Heredia University who is involved with the trial, said one volunteer had experienced weakening of his legs among other symptoms.